Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06563596 · ClinicalTrials.gov registry record · Phase 2

Epco, Zanu, Ritux for R/R FL or MZL

A Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by Reid Merryman, MD.

Recruiting
Registry status
Phase 2
Development phase
45
Enrollment target
3
Study locations

NCT06563596 is a Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Reid Merryman, MD. The registered enrollment target is 45 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06563596, a Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Reid Merryman, MD.

RECRUITING
Registry status
Phase 2
Development phase
45 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)

Conditions Studied

Lymphoma Non-Hodgkin Lymphoma Follicular Lymphoma Marginal Zone Lymphoma Refractory Lymphoma Relapsed Lymphoma

Interventions

  • DRUG Zanubrutinib
  • DRUG Epcoritamab
  • DRUG Rituximab

Study Locations (3)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Ohio

  • The Ohio State University Wexner Medical Center - Columbus

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2025-01-21
Est. Completion 2030-03-01
Phase Phase 2

Sponsor

Reid Merryman, MD

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06563596

The ClinicalTrials.gov registry entry for NCT06563596 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (91% lower). The listed sponsor is Reid Merryman, MD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.

NCT06563596 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT06563596 about?

NCT06563596 is a clinical study titled "Epco, Zanu, Ritux for R/R FL or MZL". The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research stud...

What is the current status of trial NCT06563596?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-01-21. Estimated completion is 2030-03-01.

What conditions does trial NCT06563596 study?

This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Refractory Lymphoma.

What interventions are being tested in trial NCT06563596?

The interventions under investigation include: Zanubrutinib (DRUG), Epcoritamab (DRUG), Rituximab (DRUG).

Who is sponsoring clinical trial NCT06563596?

This trial is sponsored by Reid Merryman, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06563596 being conducted?

This trial has 3 study locations across Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Non-Hodgkin Lymphoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.